KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Enterprise Value: 2020-2025

Historic Enterprise Value for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Sep 2025 value amounting to $1.5 billion.

  • Recursion Pharmaceuticals' Enterprise Value rose 2.28% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$173.5 million, marking a year-over-year decrease of 168.60%. This contributed to the annual value of $1.3 billion for FY2024, which is 23.02% down from last year.
  • Recursion Pharmaceuticals' Enterprise Value amounted to $1.5 billion in Q3 2025, which was down 4.77% from $1.5 billion recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Enterprise Value registered a high of $5.5 billion during Q2 2021, and its lowest value of -$219.1 million during Q1 2021.
  • Moreover, its 3-year median value for Enterprise Value was $1.4 billion (2024), whereas its average is $1.4 billion.
  • In the last 5 years, Recursion Pharmaceuticals' Enterprise Value spiked by 1,000.44% in 2021 and then slumped by 83.92% in 2022.
  • Quarterly analysis of 5 years shows Recursion Pharmaceuticals' Enterprise Value stood at $2.4 billion in 2021, then slumped by 61.73% to $910.3 million in 2022, then spiked by 91.27% to $1.7 billion in 2023, then dropped by 23.02% to $1.3 billion in 2024, then grew by 2.28% to $1.5 billion in 2025.
  • Its last three reported values are $1.5 billion in Q3 2025, $1.5 billion for Q2 2025, and $1.6 billion during Q1 2025.